Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?

Cowart, Kevin et al.·Diabetes·2025·
RPEP-105572025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?
Published In:
Diabetes, obesity & metabolism, 27 Suppl 7(Suppl 7), 3-13 (2025)
Database ID:
RPEP-10557

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-10557·https://rethinkpeptides.com/research/RPEP-10557

APA

Cowart, Kevin; Carris, Nicholas W. (2025). Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?. Diabetes, obesity & metabolism, 27 Suppl 7(Suppl 7), 3-13. https://doi.org/10.1111/dom.16502

MLA

Cowart, Kevin, et al. "Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?." Diabetes, 2025. https://doi.org/10.1111/dom.16502

RethinkPeptides

RethinkPeptides Research Database. "Current treatment guidelines and glycated haemoglobin goals ..." RPEP-10557. Retrieved from https://rethinkpeptides.com/research/cowart-2025-current-treatment-guidelines-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.